Showing 821-830 of 9842 results for "".
PDT: Patient Profiles for a Practice-changing Treatment
https://practicaldermatology.com/series/pdt-in-practice/pdt-patient-profiles-for-a-practice-changing-treatment/20186/Who's the ideal candidate for PDT? Other options, limitations? The advances in PDT both doctors and patients would like to see are described by Corey Hartman, MD, who shares his experiences and relates how PDT has improved his practice.Emerging Vitiligo Therapies
https://practicaldermatology.com/conferences/maui-derm-2022/emerging-vitiligo-therapies/20047/It’s really an exciting time to be treating vitiligo, says John E. Harris, MD, PhD. He reviews Phase 2 and 3 clinical trials for ruxolitinib, a topical JAK inhibitor, and the hope that the FDA could soon approve it for the treatment of vitiligo. He also discusses other possible targeted treatments iCOVID-19 Impact: Navigating Clinical Research
https://practicaldermatology.com/series/dermatology-dispatches/covid-19-impact-navigating-clinical-research/19771/Conducting clinical research studies is challenging as the majority of Americans are under stay-at-home orders for the forseeable future due to the COVID-19 pandemic, says Todd E. Schlesinger, MD. He suggests trialists do their best to say in contact with clinical research organizations, sponsors, aInjectable Beauty: New Uses for Dermal Fillers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/injectable-beauty-new-uses-for-dermal-fillers/19766/Today fillers are being used to do more than just chase wrinkles and folds, shares Jeanette Black, MD. Some exciting new uses include biostimulation with Sculptra or hyperdilute Radiesse to addresscellulite and skin laxity along with the use of intradermal hyaluronic acid-based fillers for skin hydrHad Your Fill?
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/had-your-fill/18531/If the US filler market seems robust, you should see what's available outside the US, says Hassan Galadari, MD. He provides a global perspective on fillers with a focus on up-and-coming products, the importance of understanding anatomy, and advances in recognizing and treating complications.Pearls from NYC: Oy Vey!
https://practicaldermatology.com/topics/skin-cancer-photoprotection/pearls-from-nyc-oy-vey-/18752/By Gary Goldenberg, MD and Seemal R. Desai, MDWhat happens if you shave a melanoma? Dr. Goldenberg addresses a common question from the clinic. The good news? The type of biopsy done does not appear to affect long-term survival in melanoma.Getting the Upper Hand on NMSC
https://practicaldermatology.com/topics/skin-cancer-photoprotection/getting-the-upper-hand-on-nmsc/18758/By Seemal R. Desai, MD and Anthony Rossi, MDDecide what type of treatment to use to treat the specific, biopsy-confirmed presentation, says Dr. Rossi. He shares tips to optimize topical treatment outcomes in non-melanoma skin cancer.Long-Term Effects of Neuromodulators on Aging
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/long-term-effects-of-neuromodulators-on-aging/18810/Shannon Humphrey, MD discusses the cumulative anti-aging benefits of long-term treatments with botulinum toxin type A. She shares her observations from the bench and offers a review of what the literature shows to support her recommendation for regular conservative neuromodulator treatments to improAdvances in Devices for Dermatology
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/advances-in-devices-for-dermatology/18815/M. Christine Lee, MD provides an overview of some of the new and emerging laser technologies. She discusses advances in everything from lasers and light-based devices to radiofrequency, ultrasound, and combination devices for a variety of dermatologic issues including facial rejuvenation, vaginal reThe Complex World of Biosimilars
https://practicaldermatology.com/topics/psoriasis/the-complex-world-of-biosimilars/18633/Jashin Wu, MD, discusses potential concerns with biosimilars, including the chance of inducing variable immunogenic responses compared with reference agents. Although there are currently no biosimilars approved for use in psoriasis in the United States, these agents are fast approaching market avail